{"id":30274,"date":"2020-05-09T09:01:45","date_gmt":"2020-05-09T09:01:45","guid":{"rendered":"https:\/\/www.gkseries.com\/blog\/?p=30274"},"modified":"2020-10-10T09:04:16","modified_gmt":"2020-10-10T09:04:16","slug":"csir-approved-project-to-neutralize-sars-cov-2","status":"publish","type":"post","link":"https:\/\/www.gkseries.com\/blog\/csir-approved-project-to-neutralize-sars-cov-2\/","title":{"rendered":"CSIR approved project to neutralize SARS-CoV-2"},"content":{"rendered":"\n<p>CSIR through the New Millennium Indian Technology Leadership Initiative (NMITLI) program approved a project towards the development of human monoclonal antibodies (hmAbs) that can neutralize SARS-CoV-2 in coronavirus infected patients.<\/p>\n\n\n\n<p>The project on the generation of neutralizing human monoclonal antibodies as a therapeutic strategy will be implemented by a multi-institutional and multi-disciplinary team.<\/p>\n\n\n\n<p>The team comprises academic institutes and industry with participants from NCCS, IIT-Indore, PredOmix Technologies Pvt. Ltd. and Bharat Biotech International Ltd (BBIL).<\/p>\n\n\n\n<p>The project aims to generate hmAbs to SARS-CoV-2 from the convalescent phase of COVID-19 patients and select high affinity and neutralizing antibodies.<\/p>\n\n\n\n<p>The project will also anticipate future adaptation of the virus and generate hmAbs clones that can neutralize the mutated virus so that could be readily used for combating future SARS-CoV infections.<\/p>\n\n\n\n<p>BBIL is the commercial partner of the project and is responsible for subsequent development and commercialization of the hmAbs generated.<\/p>\n\n\n\n<p>CSIR is leading the fight against COVID-19 using a multi-pronged approach and multiple models of engagement.<\/p>\n\n\n\n<p>CSIR is also supporting new ideas and projects from other academics and industries through its flagship NMITLI program.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>CSIR through the New Millennium Indian Technology Leadership Initiative (NMITLI) program approved a project towards the development of human monoclonal antibodies (hmAbs) that can neutralize SARS-CoV-2 in coronavirus infected patients. The project on the generation of neutralizing human monoclonal antibodies as a therapeutic strategy will be implemented by a multi-institutional and multi-disciplinary team. The team [&hellip;]<\/p>\n","protected":false},"author":404,"featured_media":30275,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[1173],"tags":[68],"class_list":["post-30274","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-current-affairs-may-2020","tag-science-technology-current-affairs"],"_links":{"self":[{"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/posts\/30274","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/users\/404"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/comments?post=30274"}],"version-history":[{"count":1,"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/posts\/30274\/revisions"}],"predecessor-version":[{"id":30276,"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/posts\/30274\/revisions\/30276"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/media\/30275"}],"wp:attachment":[{"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/media?parent=30274"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/categories?post=30274"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/tags?post=30274"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}